Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis Psychedelics
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc
Bullboard Posts
User Avatar Image
(15)
•••
Comment by Tony501on Jan 05, 2018 2:38pm
87 Views
Post# 27292354

RE:RE:RE:RE:Why Why Why...

RE:RE:RE:RE:Why Why Why...
Agreed Newbie, LDS will bounce back to $1.20 easy by next week. The story hasn't changed. The only change is that the plant is running a double shift every day to keep up with demand of their products which the medicinal market is begging for!! With the upcoming news all of us longs will be very happy! Wisee said it right, we will be bought out in 6 mths for $10 a share. We have so much expertise in Adelanto managing the plant and they all have lots of skin in the game. This company is set to rocket to 3-500m cap like the others very soon! Be patient and don't let the bashers second guess your decision to invest in LDS, you will be a winner. GLTA
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities